Medistim Asa Stock Current Valuation
| MEDI Stock | NOK 154.00 0.50 0.32% |
Valuation analysis of Medistim ASA helps investors to measure Medistim ASA's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Medistim ASA's price fluctuation is very steady at this time. Calculation of the real value of Medistim ASA is based on 3 months time horizon. Increasing Medistim ASA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Medistim stock is determined by what a typical buyer is willing to pay for full or partial control of Medistim ASA. Since Medistim ASA is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medistim Stock. However, Medistim ASA's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 154.0 | Real 131.25 | Hype 154.5 | Naive 174.96 |
The intrinsic value of Medistim ASA's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Medistim ASA's stock price.
Estimating the potential upside or downside of Medistim ASA helps investors to forecast how Medistim stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medistim ASA more accurately as focusing exclusively on Medistim ASA's fundamentals will not take into account other important factors: Medistim ASA Company Current Valuation Analysis
Medistim ASA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Medistim ASA Current Valuation | 4.12 B |
Most of Medistim ASA's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medistim ASA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Medistim ASA has a Current Valuation of 4.12 B. This is 71.31% lower than that of the Healthcare sector and 66.83% lower than that of the Medical Devices industry. The current valuation for all Norway stocks is 75.21% higher than that of the company.
Medistim Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medistim ASA's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medistim ASA could also be used in its relative valuation, which is a method of valuing Medistim ASA by comparing valuation metrics of similar companies.Medistim ASA is currently under evaluation in current valuation category among its peers.
Medistim Fundamentals
| Return On Equity | 0.31 | |||
| Return On Asset | 0.2 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 4.12 B | |||
| Shares Outstanding | 18.26 M | |||
| Shares Owned By Insiders | 14.97 % | |||
| Shares Owned By Institutions | 73.95 % | |||
| Price To Earning | 36.32 X | |||
| Price To Book | 12.24 X | |||
| Price To Sales | 9.15 X | |||
| Revenue | 417.82 M | |||
| Gross Profit | 320.7 M | |||
| EBITDA | 137.68 M | |||
| Net Income | 90.9 M | |||
| Cash And Equivalents | 129.49 M | |||
| Cash Per Share | 2.99 X | |||
| Total Debt | 17.08 M | |||
| Debt To Equity | 3.40 % | |||
| Current Ratio | 3.68 X | |||
| Book Value Per Share | 18.94 X | |||
| Cash Flow From Operations | 128.14 M | |||
| Earnings Per Share | 5.34 X | |||
| Target Price | 290.0 | |||
| Number Of Employees | 116 | |||
| Beta | 0.75 | |||
| Market Capitalization | 4.24 B | |||
| Total Asset | 403.24 M | |||
| Working Capital | 93 M | |||
| Current Asset | 136 M | |||
| Current Liabilities | 43 M | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 2.62 % | |||
| Net Asset | 403.24 M | |||
| Last Dividend Paid | 3.75 |
About Medistim ASA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medistim ASA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medistim ASA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medistim ASA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Medistim Stock
Medistim ASA financial ratios help investors to determine whether Medistim Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medistim with respect to the benefits of owning Medistim ASA security.